1.
Owonikoko TK, Papadopoulos KP, Johnson ML, al. E. Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data. J of Skin [Internet]. 2018Dec.17 [cited 2020Nov.29];20:S78. Available from: https://jofskin.org/index.php/skin/article/view/474